Real‐world relationship between blood biomarker‐based PhenoAge, metformin, and Alzheimer's disease
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Abstract INTRODUCTION The biological aging process could be an important Alzheimer's disease (AD) pathogenesis. Metformin might be beneficial in anti‐aging and cognition and has mixed associations with AD and/or dementia. METHODS We used a US nationwide insurance claims dataset. We used Cox models to investigate the relationship between blood biomarker‐based PhenoAge and AD and PhenoAge‐stratified comparative AD risks between metformin and sulfonylureas. RESULTS We determined that a higher PhenoAge was associated with an increased risk of AD, and that metformin, compared with sulfonylureas, was associated with a reduced risk of AD only in individuals with a lower PhenoAge (hazard ratio: 0.42 to 0.50, p
Fields of Study & Subjects
Dementia and Cognitive Impairment Research
Alzheimer's disease research and treatments
Metabolism
Diabetes
and Cancer
Publication details
- Journal / source
- Alzheimer s & Dementia Translational Research & Clinical Interventions
- Volume
- 12
- Issue
- 2
- Publication date
- 30 March 2026
- Language
- EN